Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Am J Transplant. 2022 Jan 6;22(6):1683–1690. doi: 10.1111/ajt.16931

Figure 3. Survival of heart transplant recipients before and after implementation of the new heart allocation policy by treatment type.

Figure 3

Recipients who were treated with ECMO before transplant (Panel A) experienced significantly increased 1-year survival in the post-policy cohort (69.3% [59.6%–80.6%] pre-policy vs. 87.2% [81.8%–93.0%] post-policy, log-rank P < 0.001). Recipients who were treated with IABP before transplant (Panel B) showed no significant difference in 1-year survival (92.1% [90.0%–94.3%] pre-policy vs. 91.1% [89.1%–93.2%] post-policy, log-rank P = 0.6). Recipients who were treated with mechanical ventilation before transplant (Panel C) experienced significantly increased 1-year survival in the post-policy cohort (68.2% [57.8%–80.4%] pre-policy vs. 82.9% [74.5%–92.2%] post-policy, log-rank P = 0.03). Recipients who were treated with durable LVAD before transplant (Panel D) showed no significant difference in 1-year survival (91.5% [90.6%–92.4%] pre-policy vs. 90.4% [88.5%–92.4%] post-policy, log-rank P = 0.3).